437 related articles for article (PubMed ID: 10720547)
1. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
3. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
5. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.
Yu X; Gray B; Chang S; Ward JI; Edwards KM; Nahm MH
J Infect Dis; 1999 Nov; 180(5):1569-76. PubMed ID: 10515817
[TBL] [Abstract][Full Text] [Related]
6. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
[TBL] [Abstract][Full Text] [Related]
8. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children.
Barnett ED; Pelton SI; Cabral HJ; Eavey RD; Allen C; Cunningham MJ; McNamara ER; Klein JO
Clin Infect Dis; 1999 Jul; 29(1):191-2. PubMed ID: 10433584
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the immune response following pneumococcal PD conjugate vaccination.
Schuerman L; Prymula R; Chrobok V; Dieussaert I; Poolman J
Vaccine; 2007 Mar; 25(11):1953-61. PubMed ID: 17258358
[TBL] [Abstract][Full Text] [Related]
12. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media.
Schuerman L; Prymula R; Henckaerts I; Poolman J
Vaccine; 2007 Mar; 25(11):1962-8. PubMed ID: 17258357
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
[TBL] [Abstract][Full Text] [Related]
16. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
17. Dependence of correlations between antibody titres and opsonophagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states.
Tarragó D; Aguilar L; Jansen WT; Giménez MJ; Avellón A; Granizo JJ; Casal J
Clin Microbiol Infect; 2007 Apr; 13(4):369-76. PubMed ID: 17359320
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
Scott DA; Komjathy SF; Hu BT; Baker S; Supan LA; Monahan CA; Gruber W; Siber GR; Lockhart SP
Vaccine; 2007 Aug; 25(33):6164-6. PubMed ID: 17629361
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
Silfverdal SA; Hogh B; Bergsaker MR; Skerlikova H; Lommel P; Borys D; Schuerman L
Pediatr Infect Dis J; 2009 Oct; 28(10):e276-82. PubMed ID: 20118683
[TBL] [Abstract][Full Text] [Related]
20. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.
Choo S; Zhang Q; Seymour L; Akhtar S; Finn A
J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
